$0.10
(Market cap
$1,174 Mln
Recently Viewed
Clear AllMarket cap
$1,174 Mln
Revenue (TTM)
$110 Mln
P/E Ratio
--
P/B Ratio
19.3
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-14.8 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-2.6
Debt to Equity
-1.2
Book Value
$--
EPS
$-3.2
Face value
--
Shares outstanding
48,682,280
CFO
$-479.74 Mln
EBITDA
$-557.50 Mln
Net Profit
$-666.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
UroGen Pharma (URGN)
| 0.1 | 36.5 | 9.9 | 117.8 | 26.5 | 3.1 | -- |
|
BSE Sensex
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
UroGen Pharma (URGN)
| 119.9 | 69.1 | -6.7 | -47.2 | -46.0 | -22.5 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
UroGen Pharma (URGN)
|
23.4 | 1,173.7 | 109.8 | -153.5 | -125.8 | 268.6 | -- | 19.3 |
| 0.4 | 6.0 | 2.4 | -11.5 | -475.0 | -117.6 | -- | 1.0 | |
| 2.6 | 293.1 | 72.8 | 35.3 | 0.0 | 44.8 | 8.2 | 2.7 | |
| 0.8 | 214.2 | 0.0 | 1,235.5 | -- | 126.2 | 0 | 0.1 | |
| 0.8 | 9.5 | 3.9 | -8.5 | -318.9 | 1107 | -- | 6.2 | |
| 0.6 | 4.1 | 0.0 | -10.3 | -- | -64.2 | -- | 0.3 | |
| 71.4 | 242.8 | 19.4 | -6.1 | -30.2 | -23.7 | -- | 10.6 |
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel... technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey. Read more
President, CEO & Director
Ms. Elizabeth A. Barrett
President, CEO & Director
Ms. Elizabeth A. Barrett
Headquarters
Princeton, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of UroGen Pharma Ltd (URGN) is $23.44 (NASDAQ) as of 30-Apr-2026 11:36 EDT. UroGen Pharma Ltd (URGN) has given a return of 26.46% in the last 3 years.
Since, TTM earnings of UroGen Pharma Ltd (URGN) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-7.32
|
-10.66
|
|
2024
|
-3.61
|
-52.02
|
|
2023
|
-4.25
|
-6.67
|
|
2022
|
-1.86
|
-2.28
|
|
2021
|
-1.89
|
24.87
|
The 52-week high and low of UroGen Pharma Ltd (URGN) are Rs 30.00 and Rs 3.42 as of 30-Apr-2026.
UroGen Pharma Ltd (URGN) has a market capitalisation of $ 1,174 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in UroGen Pharma Ltd (URGN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.